UNRESECTABLE NEUROENDOCRINE CARCINOMA

Clinical trials for UNRESECTABLE NEUROENDOCRINE CARCINOMA explained in plain language.

Never miss a new study

Get alerted when new UNRESECTABLE NEUROENDOCRINE CARCINOMA trials appear

Sign up with your email to follow new studies for UNRESECTABLE NEUROENDOCRINE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New drug combo shows promise for Tough-to-Treat cancers

Disease control Ongoing

This early-phase trial tests the safety and best dose of a new drug (BAY 1895344) when given with standard chemotherapy (irinotecan or topotecan) for people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic …

Matched conditions: UNRESECTABLE NEUROENDOCRINE CARCINOMA

Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Jun 16, 2026 12:50 UTC

UNRESECTABLE NEUROENDOCRINE CARCINOMA

Get alerted when new UNRESECTABLE NEUROENDOCRINE CARCINOMA trials appear

New drug combo shows promise for Tough-to-Treat cancers